FDA Accepts Allergan Aesthetics' Premarket Approval Application for SKINVIVE by JUVÉDERM® to Improve Neck Appearance

Reuters
06-30
FDA Accepts Allergan Aesthetics' Premarket Approval Application for SKINVIVE by JUVÉDERM® to Improve Neck Appearance

AbbVie Inc., through its subsidiary Allergan Aesthetics, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental premarket approval application for SKINVIVE by JUVÉDERM®. This application seeks to expand the indication of SKINVIVE to include the reduction of neck lines, aiming to improve neck appearance. Already approved in the U.S. for enhancing cheek skin smoothness in adults over 21, SKINVIVE by JUVÉDERM® could become the first hyaluronic acid injectable treatment option targeting neck lines if approved. The application is supported by a clinical study that met all primary and secondary endpoints.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AbbVie Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG20317) on June 30, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10